Heparan sulfate proteoglycans and their modification as promising anticancer targets in hepatocellular carcinoma

PMC full text:

Published online 2021 Jan 4. doi: 10.3892/ol.2021.12434

Copyright/LicenseRequest permission to reuse: Copyright : © Alshehri et al.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Table II.

Summary of studies that used heparanase inhibitors for the treatment of HCC.

Model	Summary	Cell type	(Refs.)
Human	Downregulation of heparanase enhances the suppression of invasion, migration and adhesion in HCC	HepG2, BEL-7402, and HCCLM3	(77,78)
	Administering 160 mg/day PI-88 produces significant clinical advantages for patients with HCC	Liver cells	(79,80)
Rats	Suramin exerts antitumor activity in HCC through the deactivation of heparanase	Liver cells	(15)

HCC, hepatocellular carcinoma.